Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2.
Conclusion In patients without underlying cardiac disease at baseline, the addition of trastuzumab to adjuvant anthracycline and taxane-based chemotherapy does not result in long-term worsening of cardiac function, cardiac symptoms, or health-related quality of life. The DASI questionnaire may provide a simple and useful tool for monitoring patient-reported changes that reflect cardiac function.
PMID: 29072977 [PubMed - indexed for MEDLINE]
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Ganz PA, Romond EH, Cecchini RS, Rastogi P, Geyer CE, Swain SM, Jeong JH, Fehrenbacher L, Gross HM, Brufsky AM, Flynn PJ, Wahl TA, Seay TE, Wade JL, Biggs DD, Atkins JN, Polikoff J, Zapas JL, Mamounas EP, Wolmark N Tags: J Clin Oncol Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Diabetes | Endocrinology | Herceptin | Hypertension | PET Scan | Study | Toxicology